title: Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans.
abstract: The absorption, metabolism, and excretion of the oral direct thrombin inhibitor, ximelagatran, and its active form, melagatran, were separately investigated in rats, dogs, and healthy male human subjects after administration of oral and intravenous (i.v.) single doses. Ximelagatran was rapidly absorbed and metabolized following oral administration, with melagatran as the predominant compound in plasma. Two intermediates (ethyl-melagatran and OH-melagatran) that were subsequently metabolized to melagatran were also identified in plasma and were rapidly eliminated. Melagatran given i.v. had relatively low plasma clearance, small volume of distribution, and short elimination half-life. The oral absorption of melagatran was low and highly variable. It was primarily renally cleared, and the renal clearance agreed well with the glomerular filtration rate. Ximelagatran was extensively metabolized, and only trace amounts were renally excreted. Melagatran was the major compound in urine and feces after administration of ximelagatran. Appreciable quantities of ethyl-melagatran were also recovered in rat, dog, and human feces after oral administration, suggesting reduction of the hydroxyamidine group of ximelagatran in the gastrointestinal tract, as demonstrated when ximelagatran was incubated with feces homogenate. Polar metabolites in urine and feces (all species) accounted for a relatively small fraction of the dose. The bioavailability of melagatran following oral administration of ximelagatran was 5 to 10% in rats, 10 to 50% in dogs, and about 20% in humans, with low between-subject variation. The fraction of ximelagatran absorbed was at least 40 to 70% in all species. First-pass metabolism of ximelagatran with subsequent biliary excretion of the formed metabolites account for the lower bioavailability of melagatran.
authors.affiliation: AstraZeneca R&D Mölndal, Sweden. ulf.eriksson@astrazeneca.com
authors.forename: Ulf G
authors.initials: UG
authors.lastname: Eriksson
authors.forename: Ulf
authors.initials: U
authors.lastname: Bredberg
authors.forename: Kurt-Jürgen
authors.initials: KJ
authors.lastname: Hoffmann
authors.forename: Anneli
authors.initials: A
authors.lastname: Thuresson
authors.forename: Margareth
authors.initials: M
authors.lastname: Gabrielsson
authors.forename: Hans
authors.initials: H
authors.lastname: Ericsson
authors.forename: Martin
authors.initials: M
authors.lastname: Ahnoff
authors.forename: Kristina
authors.initials: K
authors.lastname: Gislén
authors.forename: Gunnar
authors.initials: G
authors.lastname: Fager
authors.forename: David
authors.initials: D
authors.lastname: Gustafsson
mesh_terms: D000042:Absorption / Q000502:physiology; D000284:Administration, Oral; D000328:Adult; D000818:Animals; D019540:Area Under Curve; D001384:Azetidines / Q000097:blood / Q000737:chemistry / Q000493:pharmacokinetics* / Q000652:urine; D001596:Benzylamines; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D051381:Rats; D017207:Rats, Sprague-Dawley; D013917:Thrombin / Q000037:antagonists & inhibitors* / Q000378:metabolism; D014018:Tissue Distribution / Q000502:physiology
chemical_list: D001384:Azetidines; D001596:Benzylamines; C426686:ximelagatran; D013917:Thrombin